质量水平
ligand
(Trimethylammoniumethyl)
无菌性
sterile (Caustic Stable)
产品线
Eshmuno®
形式
resin
特殊分析物
MAbs
参数
1000 cm/hr flow rate
1000 cm/hr max. flow rate
8 bar max. pressure
基质活性基团
polymer, polyvinyl ether
平均粒径
85 μm
容量
150 mg binding capacity (BSA/mg of resin)
~150 mg, BSA binding capacity
转变温度
flash point 35 °C (own results)
密度
1 g/cm3 at 20 °C
应用
recombinant protein
vaccine development
分离技术
anion exchange
mixed mode
储存温度
2-30°C
正在寻找类似产品? 访问 产品对比指南
一般描述
特点和优势
- Purification of acidic and neutral proteins and peptides from different sources, including plasma
Superior productivity for downstream processing of biomolecules
- High flow rate versus pressure-flow behavior
- Excellent removal of impurities, such as HCP, leached Protein A, and viruses
- Robust and safe packing procedures
- Strong chemical stability
包装
- 1.20079.0100: Eshmuno® Q Resin 100ml
- 1.20079.0010: Eshmuno® Q Resin 10ml
- 1.20079.0500: Eshmuno® Q Resin 500ml
- 1.20079.5000: Eshmuno® Q Resin 5L
分析说明
Microscopic evaluation: Spherical particles, no agglomerates, no fines.
Extractable matter (water): ≤ 0.08 %
Ionic capacity: 90 - 190 µeq/ml
Performance test (conalbumin): 9 - 19 mS/cm
Performance test (human serum albumin): 20 - 30 mS/cm
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 1.0 bar
Protein binding capacity(bovine serum albumin): 120 - 190 mg/ml
Particle size (50-120 µm): ≥ 80 %
Particle size (d50): 75 - 95 µm
Cerium: ≤ 30 µg/g
Endotoxins: ≤ 1.00 EU/ml
TAMC (total aerobic microbial count): ≤ 100 CFU/ml
TYMC (total yeast and mould count): ≤ 100 CFU/ml
法律信息
Not finding the right product?
Try our 产品选型工具.
警示用语：
Warning
危险声明
危险分类
Flam. Liq. 3
WGK
WGK 1
闪点(°F)
95.0 °F
闪点(°C)
35 °C
商品
See case study examples of how to optimize chromatographic purification of plasmid DNA for Biopharmaceutical Applications.
Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.
A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.
Learn more one the attenuated viral vaccines manufacturing process: cell culture, clarification, nuclease treatment, chromatography, and sterile filtration.
相关内容
可使用相对模式化的工艺生产活载体疫苗。但挑战依然存在，包括由于无菌过滤、载体聚集和扩大化贴壁培养而导致的产量损失。了解有关该核心平台技术的所有信息，以及如何利用合作增强的专业知识克服生产难题。
A templated process produces live vector vaccines. Challenges: yield loss, filtration, aggregation, scaling. Collaboration overcomes manufacturing hurdles.
Tailored viral vaccine manufacturing addresses virus-specific challenges through collaboration.
病毒疫苗的生产较为复杂，且并无模式化的生产方法。每一道工艺都必须根据病毒的形状、大小、性质、理化行为、稳定性和宿主特异性进行调整。了解有关该核心平台技术的所有信息，以及如何利用合作增强的专业知识克服生产难题。
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门